Zavala-Cerna Maria G, Segura-Cobos Midrori, Gonzalez Ricardo, Zavala-Trujillo Isidro G, Navarro-Perez Silvia F, Rueda-Cruz Jose A, Satoscoy-Tovar Fernando A
Immunology Department, International Program of Medicine, Universidad Autonoma de Guadalajra, Guadalajara, Jal, Mexico.
Facultad de Biología, Instituto de Ciencias Exactas y Terrestres, Universidad Autonoma de Guadalajara, Guadalajara, Jal, Mexico.
Can J Infect Dis Med Microbiol. 2020 Jun 4;2020:2967260. doi: 10.1155/2020/2967260. eCollection 2020.
Urinary tract infections (UTIs) affect up to 150 million individuals annually worldwide, mainly due to () and . The emergence and spread of multidrug-resistant (MDR) bacteria are increasing, representing one of the biggest threats for human health. The objective of our study was to describe antimicrobial patterns of resistance and identify risk factors associated with MDR uropathogens.
We conducted a cross-sectional study in 296 patients with community-acquired UTI who underwent clinical and microbiologic analysis, and clinical associations to MDR uropathogens were investigated. . Microbiological analysis included (55%), ESBL- (26%), (6%), (5%), and others (8%). Higher frequencies of MDR bacteria were found among ESBL-, with resistance to ampicillin (100%), ceftriaxone (96%), gentamicin (57%), ciprofloxacin (89%), and TMP/SMX (53%). However, they were sensitive to fosfomycin (6.6%), nitrofurantoin (1.3%), and carbapenems (0%). Fosfomycin MIC90 for ESBL- was 5.78 g/mL. The only clinical variable with significant association to ESBL producers was the presence of comorbidities: hypertension and type 2 diabetes mellitus with an OR (95%CI) of 2.5(1.3 - 4.9)( < 0.01) and 2.8(1.2 - 6.7)( < 0.05), respectively.
In the majority of cases, resistance rates to commonly prescribed antimicrobials in UTIs were high, except for fosfomycin, nitrofurantoin, and carbapenems. To provide appropriate treatment, both the identification of risk factors and the uropathogen would be important. An active surveillance in UTIs in the community is required since the proportion of ESBL producers is increasing.
全球每年有多达1.5亿人受到尿路感染(UTIs)影响,主要原因是()和()。多重耐药(MDR)细菌的出现和传播日益增加,是人类健康面临的最大威胁之一。我们研究的目的是描述抗菌药物耐药模式,并确定与MDR尿路病原体相关的危险因素。
我们对296例社区获得性UTI患者进行了横断面研究,这些患者接受了临床和微生物学分析,并调查了与MDR尿路病原体的临床关联。()。微生物学分析包括(55%)、产超广谱β-内酰胺酶(ESBL-)(26%)、(6%)、(5%)和其他(8%)。在产ESBL-细菌中发现MDR细菌的频率更高,对氨苄西林耐药率为(100%)、头孢曲松(96%)、庆大霉素(57%)、环丙沙星(89%)和复方磺胺甲恶唑(TMP/SMX)(53%)。然而,它们对磷霉素敏感率为(6.6%)、呋喃妥因(1.3%),对碳青霉烯类耐药率为(0%)。产ESBL-细菌的磷霉素MIC90为5.78μg/mL。与产ESBL-细菌有显著关联的唯一临床变量是合并症的存在:高血压和2型糖尿病,其比值比(95%可信区间)分别为2.5(1.3 - 4.9)(P<0.01)和2.8(1.2 - 6.7)(P<0.05)。
在大多数情况下,UTIs中对常用抗菌药物的耐药率很高,磷霉素、呋喃妥因和碳青霉烯类除外。为了提供适当的治疗,识别危险因素和尿路病原体都很重要。由于产ESBL-细菌的比例在增加,社区中需要对UTIs进行积极监测。